Seeking Alpha

Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease...

Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease drug Esbriet gained approval with a Germany review committee. The action clears a path for the treatment to be approved by the nation's health insurers and helps increase confidence that France will also allow the therapy.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|